Zimmer Biomet stock (US98956P1021): Leading medical device maker for orthopedics

Zimmer Biomet focuses on musculoskeletal healthcare, providing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, and dental solutions. The company reported full-year 2023 revenue of $7.4 billion in its annual filing published March 5, 2024, reflecting steady demand in joint replacement procedures.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Zimmer Biomet: core business model

Zimmer Biomet develops, manufactures, and markets orthopedic reconstructive products primarily for knee and hip replacements. Its portfolio includes cementless and cemented implants, as well as robotic-assisted surgical systems like the ROSA platform. The company operates through two main segments: Products & Services, which generates the bulk of revenue from surgical devices, and BioContract Manufacturing Services.

With a presence in over 100 countries, Zimmer Biomet emphasizes innovation in biomaterials and personalized medicine. U.S. investors track the firm for its exposure to the aging population driving elective surgeries, a trend bolstered by Medicare reimbursement policies.

Main revenue and product drivers for Zimmer Biomet

Knee systems account for roughly 35% of revenue, followed by hips at 30%, according to the 2023 10-K filing dated February 2024. Sports medicine and biologics contribute growth via products like the BioCartilage for cartilage repair. The dental segment, including implants and abutments, adds diversification.

Robotics and digital technologies, such as the Persona IQ smart knee launched in 2024, position Zimmer Biomet in high-margin areas. These drivers support resilience for NYSE-listed stocks amid healthcare spending in the U.S. economy.

Industry trends and competitive position

The orthopedic devices market is projected to grow at 5% annually through 2030, driven by rising osteoarthritis cases in the U.S., per Statista as of 2024. Zimmer Biomet competes with Stryker, DePuy Synthes (J&J), and Smith & Nephew, holding about 15% global share in hips and knees.

Its competitive edge lies in an extensive patent portfolio exceeding 11,000 active filings and a direct sales force reaching 8,000 surgeons. For U.S. retail investors, this translates to stable demand from domestic procedures comprising over 50% of revenue.

Why Zimmer Biomet matters for US investors

Listed on the NYSE under ZBH, Zimmer Biomet offers U.S. investors pure-play exposure to orthopedics, a $50 billion+ U.S. market. The company's 70%+ revenue from the Americas underscores its alignment with domestic healthcare trends like outpatient surgeries.

Dividend payments, such as the $0.24 quarterly payout declared in early 2024, appeal to income-focused portfolios amid volatility in broader tech-heavy indices.

Conclusion

Zimmer Biomet remains a cornerstone in orthopedic innovation, with a diversified portfolio supporting long-term healthcare demand. U.S. investors monitor its robotics advancements and market share amid competitive pressures. Ongoing filings provide transparency into performance metrics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.